FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128661133> ?p ?o ?g. }

• W2128661133 endingPage "2587" @default.
• W2128661133 startingPage "2586" @default.
• W2128661133 abstract "In this issue of theJournal of Clinical Oncology, Stevens et al 1 present the 5-year results of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor study (MMT 89), an important and well-analyzed clinical trial. The discerning reader will immediately discover many similarities with, yet some philosophical differences from, the Children’s Oncology Group approach to this heterogeneous disease. The differences in the treatment approaches and outcome data between the MMT 89 study and the Intergroup Rhabdomyosarcoma Study Group (IRSG) IRSIV 2 identify important issues plaguing oncologists managing this complex malignant disease. Both the MMT 89 and IRS-IV studies utilized similar eligibility criteria, recommended common pretreatment staging examinations, and differentiated the alveolar subtype from the more common embryonal subtype. Both studies used the TNM staging system and reported results in patients with nonmetastatic disease. Both studies built on data from previously published group studies. Both groups value each other’s work and have collaborated effectively in workshops pooling data to better understand the unique problems arising in particularly difficult sites: parameningeal, 3 orbit, 4 and bladder/prostate. 5 Investigators from both groups recognize the importance of analysis of the total treatment administered, and of the early and late effects of the disease and its treatment. The differences between the MMT and IRSG studies are largely those of management and treatment philosophy. An MMT 89 study objective was to reduce use of local therapy, with initial front-line chemotherapy followed by alternate second-line chemotherapy in the event of a poor response to initial chemotherapy, before local therapy was administered. Surgical resection was the preferred local therapy, with radiation therapy only after incomplete surgical resection, documented nodal involvement, and poor clinical response to combination chemotherapy. The study was designed to avoid “radical” surgery and radiation. Overall survival was the primary end point, accepting the possibility of poorer event-free survival (EFS) and the necessity of salvage therapy for those who relapsed. The primary IRS-IV study objective was early local therapy after induction chemotherapy, using radiation therapy for those with nonresected disease, with a goal to preserve form and organ function. EFS was the valued end point, to avoid relapse and the requisite salvage therapy. Thus, the IRSG study used radiation for all patients with an incompletely resected tumor, and for all with the alveolar subtype. IRS-IV also used radiation as the preferred method of local therapy for all patients with parameningeal disease, not just those age 3 years or older. As IRS-IV 5-year data are now available for comparison with the MMT 89 data, we have summarized the characteristics, eligibility criteria, and outcome results in Tables 1 and 2. The IRS-IV histologic data are restricted to those with embryonal and alveolar histologic subtypes. The update reveals that IRS-IV therapy produced superior EFS and somewhat better overall survival than the MMT 89 therapy. In some subsets of patients defined by primary site, the survival differences are striking (limbs, nonparameningeal head and neck); in others, the results are largely similar (genitourinary). Nevertheless, the overall impression is that survival for most patient subsets seems better with the use of initial local therapy, including irradiation, a philosophy of the IRSG studies. Total burden of therapy is important to all investigators. In the MMT 89 study, less than half the patients were cured without significant local therapy. Salvage therapy often requires more toxic treatment than initial therapy, is accompanied by more morbidity, and is not always successful. The philosophical difference in the initial approach to therapy is particularly pronounced in the case of primary orbital tumors, in which chemotherapy alone resulted in" @default.
• W2128661133 created "2016-06-24" @default.
• W2128661133 creator A5028949419 @default.
• W2128661133 creator A5090006346 @default.
• W2128661133 date "2005-04-20" @default.
• W2128661133 modified "2023-09-26" @default.
• W2128661133 title "Rhabdomyosarcoma: Many Similarities, a Few Philosophical Differences" @default.
• W2128661133 cites W1926287352 @default.
• W2128661133 cites W2013965194 @default.
• W2128661133 cites W2171543679 @default.
• W2128661133 cites W2202979355 @default.
• W2128661133 cites W4245891151 @default.
• W2128661133 doi "https://doi.org/10.1200/jco.2005.11.909" @default.
• W2128661133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15728222" @default.
• W2128661133 hasPublicationYear "2005" @default.
• W2128661133 type Work @default.
• W2128661133 sameAs 2128661133 @default.
• W2128661133 citedByCount "62" @default.
• W2128661133 countsByYear W21286611332012 @default.
• W2128661133 countsByYear W21286611332013 @default.
• W2128661133 countsByYear W21286611332014 @default.
• W2128661133 countsByYear W21286611332015 @default.
• W2128661133 countsByYear W21286611332016 @default.
• W2128661133 countsByYear W21286611332017 @default.
• W2128661133 countsByYear W21286611332018 @default.
• W2128661133 countsByYear W21286611332019 @default.
• W2128661133 countsByYear W21286611332020 @default.
• W2128661133 countsByYear W21286611332021 @default.
• W2128661133 countsByYear W21286611332023 @default.
• W2128661133 crossrefType "journal-article" @default.
• W2128661133 hasAuthorship W2128661133A5028949419 @default.
• W2128661133 hasAuthorship W2128661133A5090006346 @default.
• W2128661133 hasBestOaLocation W21286611331 @default.
• W2128661133 hasConcept C142724271 @default.
• W2128661133 hasConcept C2778256501 @default.
• W2128661133 hasConcept C2780844630 @default.
• W2128661133 hasConcept C71924100 @default.
• W2128661133 hasConceptScore W2128661133C142724271 @default.
• W2128661133 hasConceptScore W2128661133C2778256501 @default.
• W2128661133 hasConceptScore W2128661133C2780844630 @default.
• W2128661133 hasConceptScore W2128661133C71924100 @default.
• W2128661133 hasIssue "12" @default.
• W2128661133 hasLocation W21286611331 @default.
• W2128661133 hasLocation W21286611332 @default.
• W2128661133 hasOpenAccess W2128661133 @default.
• W2128661133 hasPrimaryLocation W21286611331 @default.
• W2128661133 hasRelatedWork W1986439267 @default.
• W2128661133 hasRelatedWork W2001230429 @default.
• W2128661133 hasRelatedWork W2080962828 @default.
• W2128661133 hasRelatedWork W2155391523 @default.
• W2128661133 hasRelatedWork W2899084033 @default.
• W2128661133 hasRelatedWork W2899145405 @default.
• W2128661133 hasRelatedWork W3023244203 @default.
• W2128661133 hasRelatedWork W4239199995 @default.
• W2128661133 hasRelatedWork W4244878610 @default.
• W2128661133 hasRelatedWork W4318601182 @default.
• W2128661133 hasVolume "23" @default.
• W2128661133 isParatext "false" @default.
• W2128661133 isRetracted "false" @default.
• W2128661133 magId "2128661133" @default.
• W2128661133 workType "article" @default.